Brief: Morphosys Presents New Longer-Term Phase 2 Results On Pelabresib

Morphosys AG

11/12/2022 22:52

Dec 11 (Reuters) - Morphosys Ag  MORG.DE :
    * EQS-NEWS: MORPHOSYS PRESENTS NEW LONGER-TERM PHASE 2
RESULTS ON
PELABRESIB IN MYELOFIBROSIS, INCLUDING POTENTIAL
DISEASE-MODIFYING ACTIVITY, AT ASH 2022
    * MORPHOSYS - MANIFEST TRIAL DATA SHOWS DURABLE IMPROVEMENTS
IN
SPLEEN VOLUME & SYMPTOM SCORE BEYOND 24 WEEKS WITH PELABRESIB IN
COMBINATION WITH RUXOLITINIB FOR JAK INHIBITOR-NAÏVE PATIENTS
    * EXPLORATORY ANALYSIS OF BIOMARKERS FROM MANIFEST TRIAL
INDICATES
POTENTIAL FOR DISEASE MODIFICATION

Source text for Eikon:  ID:nEQ5CRKMCa 
Further company coverage:  MORG.DE 
 ((Reuters.Briefs@thomsonreuters.com;))